FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601471978> ?p ?o ?g. }

• W2601471978 endingPage "167" @default.
• W2601471978 startingPage "161" @default.
• W2601471978 abstract "Objective To assess the effectiveness of intradetrusor injections of botulinum toxin type A (IDBTX-A) in children with spina bifida. Methods All patients aged less than 16 years old who underwent IDBTX-A between 2002 and 2016 at 6 institutions were included in a retrospective study. Our primary endpoint was the success rate of IDBTX-A defined as both clinical improvement (no incontinence episodes between clean intermittent catheterizations [CICs], absence of urgency, and less than 8 CICs per day) and urodynamic improvement (resolution of detrusor overactivity and normal bladder compliance for age) lasting ≥12 weeks. Predictive factors of success were assessed through univariate analysis. Results Fifty-three patients with a mean age of 8.5 years were included. All patients were under CIC and 88.7% had received anticholinergics with either poor efficacy or bothersome adverse events. The global success rate of the first injection (clinical and urodynamic) was 30%. Patients with closed spinal dysraphism had a significantly better success rate than patients with myelomeningocele (P = .002). The clinical success rate was 66% and was significantly associated with maximum urethral closure pressure (34 cm H2O vs 54.4 cm H2O, P = .02). The urodynamic success rate was 34%. Maximum cystometric capacity (P <.0001) and compliance (P = .01) significantly improved after the first IDBTX-A and maximum detrusor pressure tended to decrease (P = .09) except in the subgroup of patients with poor compliance. After a mean follow-up of 3.7 years, 23 patients (43.4%) required augmentation cystoplasty. Excluding 6 patients who were lost to follow-up, 38.3% of patients were still undergoing botulinum toxin injections at last follow-up. Conclusion In this series, despite the fact that IDBTX-A enabled clinical improvement in 66% patients, urodynamic outcomes were poor resulting in a low global success rate (30%). To assess the effectiveness of intradetrusor injections of botulinum toxin type A (IDBTX-A) in children with spina bifida. All patients aged less than 16 years old who underwent IDBTX-A between 2002 and 2016 at 6 institutions were included in a retrospective study. Our primary endpoint was the success rate of IDBTX-A defined as both clinical improvement (no incontinence episodes between clean intermittent catheterizations [CICs], absence of urgency, and less than 8 CICs per day) and urodynamic improvement (resolution of detrusor overactivity and normal bladder compliance for age) lasting ≥12 weeks. Predictive factors of success were assessed through univariate analysis. Fifty-three patients with a mean age of 8.5 years were included. All patients were under CIC and 88.7% had received anticholinergics with either poor efficacy or bothersome adverse events. The global success rate of the first injection (clinical and urodynamic) was 30%. Patients with closed spinal dysraphism had a significantly better success rate than patients with myelomeningocele (P = .002). The clinical success rate was 66% and was significantly associated with maximum urethral closure pressure (34 cm H2O vs 54.4 cm H2O, P = .02). The urodynamic success rate was 34%. Maximum cystometric capacity (P <.0001) and compliance (P = .01) significantly improved after the first IDBTX-A and maximum detrusor pressure tended to decrease (P = .09) except in the subgroup of patients with poor compliance. After a mean follow-up of 3.7 years, 23 patients (43.4%) required augmentation cystoplasty. Excluding 6 patients who were lost to follow-up, 38.3% of patients were still undergoing botulinum toxin injections at last follow-up. In this series, despite the fact that IDBTX-A enabled clinical improvement in 66% patients, urodynamic outcomes were poor resulting in a low global success rate (30%)." @default.
• W2601471978 created "2017-04-07" @default.
• W2601471978 creator A5000067707 @default.
• W2601471978 creator A5020456157 @default.
• W2601471978 creator A5023386699 @default.
• W2601471978 creator A5025197801 @default.
• W2601471978 creator A5034328762 @default.
• W2601471978 creator A5037635201 @default.
• W2601471978 creator A5056180851 @default.
• W2601471978 creator A5060063661 @default.
• W2601471978 creator A5060254037 @default.
• W2601471978 creator A5063607876 @default.
• W2601471978 creator A5069771688 @default.
• W2601471978 creator A5071004186 @default.
• W2601471978 creator A5071681972 @default.
• W2601471978 creator A5073039721 @default.
• W2601471978 creator A5076338171 @default.
• W2601471978 creator A5077521517 @default.
• W2601471978 creator A5088487307 @default.
• W2601471978 creator A5091600787 @default.
• W2601471978 date "2018-06-01" @default.
• W2601471978 modified "2023-10-09" @default.
• W2601471978 title "Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study" @default.
• W2601471978 cites W1156634504 @default.
• W2601471978 cites W1596945002 @default.
• W2601471978 cites W1932606916 @default.
• W2601471978 cites W1985267005 @default.
• W2601471978 cites W1992830759 @default.
• W2601471978 cites W2051448097 @default.
• W2601471978 cites W2058478925 @default.
• W2601471978 cites W2062168648 @default.
• W2601471978 cites W2063646746 @default.
• W2601471978 cites W2081071477 @default.
• W2601471978 cites W2089836832 @default.
• W2601471978 cites W2094506487 @default.
• W2601471978 cites W2096998881 @default.
• W2601471978 cites W2106579854 @default.
• W2601471978 cites W2132814584 @default.
• W2601471978 cites W2148263490 @default.
• W2601471978 cites W2168374754 @default.
• W2601471978 cites W2228073753 @default.
• W2601471978 cites W2404784145 @default.
• W2601471978 cites W2585977496 @default.
• W2601471978 cites W2607067487 @default.
• W2601471978 cites W2734706987 @default.
• W2601471978 cites W4210991235 @default.
• W2601471978 doi "https://doi.org/10.1016/j.urology.2018.02.033" @default.
• W2601471978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29522865" @default.
• W2601471978 hasPublicationYear "2018" @default.
• W2601471978 type Work @default.
• W2601471978 sameAs 2601471978 @default.
• W2601471978 citedByCount "29" @default.
• W2601471978 countsByYear W26014719782019 @default.
• W2601471978 countsByYear W26014719782020 @default.
• W2601471978 countsByYear W26014719782021 @default.
• W2601471978 countsByYear W26014719782022 @default.
• W2601471978 countsByYear W26014719782023 @default.
• W2601471978 crossrefType "journal-article" @default.
• W2601471978 hasAuthorship W2601471978A5000067707 @default.
• W2601471978 hasAuthorship W2601471978A5020456157 @default.
• W2601471978 hasAuthorship W2601471978A5023386699 @default.
• W2601471978 hasAuthorship W2601471978A5025197801 @default.
• W2601471978 hasAuthorship W2601471978A5034328762 @default.
• W2601471978 hasAuthorship W2601471978A5037635201 @default.
• W2601471978 hasAuthorship W2601471978A5056180851 @default.
• W2601471978 hasAuthorship W2601471978A5060063661 @default.
• W2601471978 hasAuthorship W2601471978A5060254037 @default.
• W2601471978 hasAuthorship W2601471978A5063607876 @default.
• W2601471978 hasAuthorship W2601471978A5069771688 @default.
• W2601471978 hasAuthorship W2601471978A5071004186 @default.
• W2601471978 hasAuthorship W2601471978A5071681972 @default.
• W2601471978 hasAuthorship W2601471978A5073039721 @default.
• W2601471978 hasAuthorship W2601471978A5076338171 @default.
• W2601471978 hasAuthorship W2601471978A5077521517 @default.
• W2601471978 hasAuthorship W2601471978A5088487307 @default.
• W2601471978 hasAuthorship W2601471978A5091600787 @default.
• W2601471978 hasConcept C126322002 @default.
• W2601471978 hasConcept C141071460 @default.
• W2601471978 hasConcept C144301174 @default.
• W2601471978 hasConcept C167135981 @default.
• W2601471978 hasConcept C187212893 @default.
• W2601471978 hasConcept C197934379 @default.
• W2601471978 hasConcept C2777478456 @default.
• W2601471978 hasConcept C2778478650 @default.
• W2601471978 hasConcept C38180746 @default.
• W2601471978 hasConcept C42219234 @default.
• W2601471978 hasConcept C71924100 @default.
• W2601471978 hasConceptScore W2601471978C126322002 @default.
• W2601471978 hasConceptScore W2601471978C141071460 @default.
• W2601471978 hasConceptScore W2601471978C144301174 @default.
• W2601471978 hasConceptScore W2601471978C167135981 @default.
• W2601471978 hasConceptScore W2601471978C187212893 @default.
• W2601471978 hasConceptScore W2601471978C197934379 @default.
• W2601471978 hasConceptScore W2601471978C2777478456 @default.
• W2601471978 hasConceptScore W2601471978C2778478650 @default.
• W2601471978 hasConceptScore W2601471978C38180746 @default.
• W2601471978 hasConceptScore W2601471978C42219234 @default.
• W2601471978 hasConceptScore W2601471978C71924100 @default.

• next